TellBio has filed a notice of an exempt offering of securities to raise $2,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, TellBio is raising $2,500,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Pritesh Gandhi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About TellBio
TellBio, Inc is a development stage biotechnology company based in Beverly, Massachusetts, with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutic platform, TellDx and TellRx, respectively. The foundation of the Companys approach detection of and targeting CTCs is exclusively licensed from Massachusetts General Hospital and is based on decades of academic and clinical research. TellBios vision is to free patients and their families from the tyranny of cancer via both its TellDx and TellRx platforms.TellDx is a fully functional diagnostic solution aimed at detecting live CTCs from patient liquid biopsies. TellRx is the therapeutics platform that generates novel anti-cancer medicines by specifically targeting CTCs. The synergy of these platforms offers TellBio a unique opportunity to detect CTCs via a first-in-class, best-in-class microfluidic diagnostic platform and target CTCs with novel therapeutics to improve outcomes of patients with cancer.
To learn more about TellBio, visit http://www.tellbio.com/
Contact:
Pritesh Gandhi, Chief Executive Officer
781-249-9550
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.